



2026 KNOWLEDGE-BASED HOME-STUDY CE FOR PHARMACISTS AND PHARMACY TECHNICIANS

Hot Off the Press...

Insights on the New 2025 Hypertension Guidelines

Speaker:

Joseph Saseen, PharmD, BCPS, BCACP

Associate Dean for Clinical Affairs and Professor
University of Colorado Anschutz
Skaggs School of Pharmacy
Aurora, CO

Learning Objectives

Upon completion of this CE activity, the participants will be able to do the following:

PHARMACIST & PHARMACY TECHNICIAN LEARNING OBJECTIVES

Learning Objectives for (pharmacists):

- Discuss key updates in the 2025 hypertension guideline
- Outline evidence-based recommendations to optimize patient care for patients with hypertension
- Identify therapy options for patients with hypertension, including resistant hypertension, as recommended in the 2025 hypertension guideline
- Describe emerging medications for hypertension

Learning Objectives for (pharmacy technicians):

- List the BP goal according to the 2025 hypertension guideline
- Name three drug classes recommended for the treatment of hypertension
- Identify emerging medications for resistant hypertension

Accreditation Information:

ACPE UAN: 0122-0000-26-030-H01-P/T

CPE Credit Hours: 1.0 hour (0.1 CEU) of CE credit

Release Date: March 25, 2026

Expiration Date: March 25, 2027

Sponsorship: This program is conducted solely by Premier and has no commercial or non-commercial support or sponsorship

Dr. Saseen reports that he is a member of the AMGEN Data Safety Monitoring Boards for large CV outcome trials. In keeping with Premier CE policies, the presentation has undergone mitigation procedures including peer review. None of the planners for this activity have relevant financial relationships with ineligible companies to disclose.

System Requirements to Access the Webcast: [Click here](#) to view CE webcast system requirements for the learner to complete the online activity, including the internet browser(s) supported and minimum versions of each, and the minimum memory, storage, processor, and internet

**How to obtain CE credit**

1. Log on to <https://ce.continuumofcare.premierinc.com>
2. Click on the icon that corresponds to this Home-Study CE activity
3. Register for that Home-Study CE activity
4. View and listen to the recorded activity in its entirety
5. Complete both the learning assessment questions and the activity evaluation.

Note: A passing grade of **70%** or better is required to receive CE credit. Three opportunities will be provided to successfully complete the post-test.

Once all steps above are completed, participation will be provided to CPE Monitor.



Premier, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This CE activity is provided as a free, value-added service to Premier Continuum of Care pharmacy staff.

Speaker Bio:

Dr. Joseph Saseen is a clinical pharmacist and academic leader specializing in cardiometabolic diseases. As Associate Dean for Clinical Affairs and Professor of Clinical Pharmacy and Family Medicine at the University of Colorado Anschutz Medical Campus, Dr. Saseen's expertise is centered on cardiovascular risk reduction, with a particular focus on dyslipidemia, hypertension, and population health.

Dr. Saseen actively practices in primary care, providing direct patient care for cardiometabolic conditions. His contributions to the field are recognized through his past presidency of the National Lipid Association (NLA) and his fellowship in the American College of Clinical Pharmacy (ACCP), American Society of Health-System Pharmacists (ASHP), American Pharmacists Association (APhA), and the American Heart Association (AHA). He is also honored as a Master of the NLA.

An influential voice in clinical guidelines, Dr. Saseen was a contributing author to the 2018 AHA/ACC/Multisociety cholesterol management guideline and is a member of the upcoming 2026 guideline writing committee. His scholarly work includes over 200 peer-reviewed publications and book chapters, notably the 2022 NLA Statin Intolerance Scientific Statement, the 2025 NLA/American Geriatrics Society Expert Consensus Statement on Managing Hypercholesterolemia in Adults Aged 75 Years and Older Without a History of ASCVD, and the 2025 ACC Expert Consensus Statement on Medical Weight Management Treatment for Optimization of Cardiovascular Health.